We previously reported that FcγRIIB expression was upregulated in advanced gliomas that correlated with poor survival especially in tumors with mesenchymal (MES) feature and wild type IDH1 [13], suggesting its role in suppressing immune responses in GBM. The gene discussed is FCGR2B; the disease is glioblastoma.